Researchers at the University of Illinois at Chicago and Queensland University of Technology of Australia, have developed a device that can isolate individual cancer cells from patient blood samples.
The microfluidic device works by separating the various cell types found in blood by their size. The device may one day enable rapid, cheap liquid biopsies to help detect cancer and develop targeted treatment plans. The findings are reported in the journal Microsystems & Nanoengineering.
“This new microfluidics chip lets us separate cancer cells from whole blood or minimally-diluted blood,” said Ian Papautsky, the Richard and Loan Hill Professor of Bioengineering in the UIC College of Engineering and corresponding author on the paper. “While devices for detecting cancer cells circulating in the blood are becoming available, most are relatively expensive and are out of reach of many research labs or hospitals. Our device is cheap, and doesn’t require much specimen preparation or dilution, making it fast and easy to use.”
The ability to successfully isolate cancer cells is a crucial step in enabling liquid biopsy where cancer could be detected through a simple blood draw. This would eliminate the discomfort and cost of tissue biopsies which use needles or surgical procedures as part of cancer diagnosis. Liquid biopsy could also be useful in tracking the efficacy of chemotherapy over the course of time, and for detecting cancer in organs difficult to access through traditional biopsy techniques, including the brain and lungs.
However, isolating circulating tumor cells from the blood is no easy task, since they are present in extremely small quantities. For many cancers, circulating cells are present at levels close to one per 1 billion blood cells. “A 7.5-milliliter tube of blood, which is a typical volume for a blood draw, might have ten cancer cells and 35-40 billion blood cells,” said Papautsky. “So we are really looking for a needle in a haystack.”
Microfluidic technologies present an alternative to traditional methods of cell detection in fluids. These devices either use markers to capture targeted cells as they float by, or they take advantage of the physical properties of targeted cells — mainly size — to separate them from other cells present in fluids.
Papautsky and his colleagues developed a device that uses size to separate tumor cells from blood. “Using size differences to separate cell types within a fluid is much easier than affinity separation which uses ‘sticky’ tags that capture the right cell type as it goes by,” said Papautsky. “Affinity separation also requires a lot of advanced purification work which size separation techniques don’t need.”
The Latest on: Cancer blood test
via Google News
The Latest on: Cancer blood test
- New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard®on January 12, 2021 at 11:45 am
PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced data published today in Cancer Prevention Research, a Journal of the American Association ...
- Pituitary Cancer Market | Product Estimates & Strategy Framework, Forecasts, 2018-2025on January 12, 2021 at 6:35 am
The global pituitary cancer market is showing growth opportunities at a 9.4% CAGR in the years between 2017 and 2023, which has been defined by Market Research Future (MRFR) as the forecast period.
- CES 2021 Jun Zhi integrated Taiwan's top research teams to develop SAA Cancer Screening Serviceson January 12, 2021 at 6:34 am
Zhi, a Taiwan-based biomedical team, developed the SAA Cancer Screening Service. This service detects early-stage gastric and ...
- Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposiumon January 12, 2021 at 6:25 am
PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual ...
- Freenome’s Multiomics Blood Test Shows Promising Results in Detecting Colorectal Advanced Adenomas in a Prospective, Multi-Center Clinical Studyon January 12, 2021 at 6:00 am
Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood draw, today announced that it will be presenting ...
- JPM: Illumina inks multiple cancer diagnostic partnerships to complement upcoming Grail acquisitionon January 12, 2021 at 4:55 am
Following its $8 billion pitch last year to acquire Grail and its upcoming multi-tumor blood test, Illumina is planning a deeper dive into cancer genomics with a slew of new biopharma development ...
- GRAIL Confirms Q2 2021 Introduction of Galleri, First-of-Kind Multi-Cancer Early Detection Blood Teston January 12, 2021 at 1:52 am
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today confirmed it expects to introduce Galleri™, its multi-cancer early detection blood test, in the ...
- 25 Facts About Cancer That Could Help You Save a Lifeon January 11, 2021 at 9:23 am
The word “cancer” can be a little scary. And getting a cancer diagnosis can be, too.“Patients ask us this question all the time,” says Megan Kruse, MD, a breast oncologist with the Cleveland Clinic.
- Cancer Diagnosis Might Be Wrong for Many English Bulldogson January 11, 2021 at 6:51 am
New research on illness in English bulldogs has discovered a previously unknown genetic health condition -- and could save the lives of some beloved family pets. Researchers were attempting to better ...
- Amgen, AstraZeneca, Bristol Myers Squibb To Evaluate GRAIL's Cancer Early Detection Teston January 11, 2021 at 6:12 am
GRAIL has developed and validated a novel approach to detect early cancer signals in blood. Cancer MRD testing is used in clinical and research applications to detect the presence or absence of ...
via Bing News